Therapeutic Area | MeSH |
---|---|
mental disorders | D001523 |
Brand Name | Status | Last Update |
---|---|---|
escitalopram | ANDA | 2024-01-18 |
escitalopram oral solution | ANDA | 2023-09-01 |
escitalopram oxalate | ANDA | 2024-01-19 |
lexapro | New Drug Application | 2023-11-17 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
major depressive disorder | EFO_0003761 | D003865 | F22 |
Expiration | Code | ||
---|---|---|---|
ESCITALOPRAM OXALATE, LEXAPRO, ABBVIE | |||
2026-05-12 | NPP |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Major depressive disorder | D003865 | EFO_0003761 | F22 | 14 | 38 | 47 | 61 | 41 | 193 |
Depression | D003863 | — | F33.9 | 7 | 20 | 22 | 60 | 49 | 150 |
Healthy volunteers/patients | — | — | — | 24 | — | — | 4 | 6 | 34 |
Anxiety disorders | D001008 | EFO_0006788 | F41.1 | 4 | 3 | 7 | 9 | 9 | 31 |
Depressive disorder | D003866 | EFO_1002014 | F32.A | 5 | 4 | 8 | 6 | 5 | 27 |
Anxiety | D001007 | EFO_0005230 | F41.1 | — | 1 | 5 | 6 | 7 | 18 |
Obsessive-compulsive disorder | D009771 | EFO_0004242 | F42 | — | — | 2 | 9 | 4 | 15 |
Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 2 | 8 | 3 | 13 |
Sleep initiation and maintenance disorders | D007319 | — | F51.01 | — | 3 | 2 | 6 | 2 | 12 |
Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 1 | 2 | 3 | 3 | 3 | 11 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Treatment-resistant depressive disorder | D061218 | — | — | 1 | — | 7 | — | 2 | 10 |
Neoplasms | D009369 | — | C80 | 1 | 1 | 4 | — | 2 | 8 |
Cocaine-related disorders | D019970 | — | F14 | 1 | 5 | 1 | — | — | 6 |
Hot flashes | D019584 | — | — | — | — | 1 | — | 4 | 5 |
Mood disorders | D019964 | EFO_0004247 | F30-F39 | — | 1 | 1 | — | 2 | 4 |
Parkinson disease | D010300 | EFO_0002508 | G20 | — | 2 | 2 | — | 1 | 4 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | 2 | — | 1 | 4 |
Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | — | 1 | — | 2 | 3 |
Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | 1 | 1 | — | — | 2 |
Hiv infections | D015658 | EFO_0000764 | B20 | — | — | 2 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Cardiovascular diseases | D002318 | HP_0001626 | — | — | 1 | — | — | 5 | 6 |
Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 1 | — | — | 2 | 3 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | — | — | 1 | 2 |
Insulin resistance | D007333 | HP_0000855 | E88.819 | — | 1 | — | — | 1 | 2 |
Menopause | D008593 | EFO_0003922 | N95 | — | 1 | — | — | 1 | 2 |
Ischemic stroke | D000083242 | — | — | 1 | 2 | — | — | — | 2 |
Autistic disorder | D001321 | HP_0000717 | F84.0 | — | 1 | — | — | 1 | 2 |
Male infertility | D007248 | EFO_0004248 | N46 | — | 1 | — | — | — | 1 |
Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | — | 1 | — | — | — | 1 |
Prediabetic state | D011236 | EFO_1001121 | R73.03 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Spinal cord injuries | D013119 | EFO_1001919 | — | 2 | — | — | — | 1 | 3 |
Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | 1 | 2 |
Autism spectrum disorder | D000067877 | HP_0000729 | F84.0 | 1 | — | — | — | 1 | 2 |
Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | 2 | — | — | — | — | 2 |
Stress urinary incontinence | D014550 | HP_0010992 | — | 1 | — | — | — | — | 1 |
Fecal incontinence | D005242 | — | R15 | 1 | — | — | — | — | 1 |
Hepacivirus | D016174 | — | — | 1 | — | — | — | — | 1 |
Premature ejaculation | D061686 | HP_0012876 | F52.4 | 1 | — | — | — | — | 1 |
Hypercapnia | D006935 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 5 | 5 |
Taste disorders | D013651 | — | — | — | — | — | — | 3 | 3 |
Pharmacokinetics | D010599 | — | — | — | — | — | — | 2 | 2 |
Cognition | D003071 | EFO_0003925 | — | — | — | — | — | 2 | 2 |
Drug interactions | D004347 | — | — | — | — | — | — | 1 | 1 |
Perimenopause | D047648 | — | — | — | — | — | — | 1 | 1 |
Intractable pain | D010148 | — | — | — | — | — | — | 1 | 1 |
Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 1 | 1 |
Wounds and injuries | D014947 | — | T14.8 | — | — | — | — | 1 | 1 |
Chronic disease | D002908 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Escitalopram |
INN | escitalopram |
Description | Escitalopram is a 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile that has S-configuration at the chiral centre. It is the active enantiomer of citalopram. It has a role as an antidepressant and an EC 3.4.21.26 (prolyl oligopeptidase) inhibitor. It is a conjugate base of an escitalopram(1+). It is an enantiomer of a (R)-citalopram. |
Classification | Small molecule |
Drug class | Selective serotonin reuptake inhibitor (SSRI) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21 |
PDB | — |
CAS-ID | 128196-01-0 |
RxCUI | — |
ChEMBL ID | CHEMBL1508 |
ChEBI ID | 36791 |
PubChem CID | 146570 |
DrugBank | DB01175 |
UNII ID | 4O4S742ANY (ChemIDplus, GSRS) |